Skip to main content

Explore our strategy and projects
to learn about the future of our company

Results FY 2023 (€/MLN)

1,148

Revenues

375

Adjusted EBITDA

224

Adjusted net profit

209

Free cash flow

Stock price

Discover more

Press releases

16/07/24 - 8:31

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument

05/06/24 - 5:07

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX®
Learn More

Presentations

10/05/24

Q1 2024 Results Presentation
Learn More
Presentations
Calendar

Calendar

Jefferies - London Healthcare Conference

London

IR

View all

LIAISON PLEX® System: the new multiplexing platform of the Group

Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.

Liaison Plex

Keep
in touch

Sign up for our investor alerts
and stay informed
on the latest developments

Privacy Statement *
The Undersigned Confirms That The Information. Provided Pursuant To Leg. Decree No. 196/2003 Has Been Read And Accepted.